Company intelligence / Profile preview

Aquoralon Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Aquilon Pharma has launched a Phase II clinical trial for COVID-19 patients in the acute respiratory phase and has ongoing clinical trials. The company focuses on improving efficacy of inhaled drugs for respiratory conditions.

Therapeutic areas: PulmonologyOther
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

AQ001V

Preclinical

Partnerships

ISAB (PreciseInhale® system)Aeronext partners

Beyond the preview

Go deeper on Aquoralon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquoralon Pharmaceuticals.